These preliminary results depict that pMSCs not only inhibit agonist‐induced platelet activation but DBMSCs also inhibit ox‐LDL‐induced‐CD36‐mediated platelet aggregation providing a direct link between pMSCs therapy, hyperlipidaemia and atherosclerosis. Here, CD36 is linked to hyperlipidemia.